share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q：2024財年二季報
美股SEC公告 ·  2024/08/14 20:14

Moomoo AI 已提取核心訊息

Agape ATP Corporation reported Q2 2024 revenue of $313,039, representing a 3% increase from $303,935 in Q2 2023. The growth was driven by a 33.1% increase in complementary health therapies revenue to $230,536, which offset a 67.7% decline in network marketing business revenue due to limited product range availability.Gross profit margin decreased to 61.8% from 64.5% year-over-year, while operating expenses increased 16.5% to $647,146, primarily due to higher general and administrative expenses from director compensation and Nasdaq listing fees. The company recorded other income of $31,110 compared to expenses of $22,355 in the prior year period.Net loss widened to $432,315 from $379,449 in Q2 2023. As of June 30, 2024, the company maintained a strong liquidity position with $3.16 million in cash and cash equivalents, though down from $4.83 million at year-end 2023. Management continues to focus on expanding its complementary health therapies business while working to address challenges in the network marketing segment.
Agape ATP Corporation reported Q2 2024 revenue of $313,039, representing a 3% increase from $303,935 in Q2 2023. The growth was driven by a 33.1% increase in complementary health therapies revenue to $230,536, which offset a 67.7% decline in network marketing business revenue due to limited product range availability.Gross profit margin decreased to 61.8% from 64.5% year-over-year, while operating expenses increased 16.5% to $647,146, primarily due to higher general and administrative expenses from director compensation and Nasdaq listing fees. The company recorded other income of $31,110 compared to expenses of $22,355 in the prior year period.Net loss widened to $432,315 from $379,449 in Q2 2023. As of June 30, 2024, the company maintained a strong liquidity position with $3.16 million in cash and cash equivalents, though down from $4.83 million at year-end 2023. Management continues to focus on expanding its complementary health therapies business while working to address challenges in the network marketing segment.
Agape ATP公司報告了2024年第二季度營業收入爲313,039美元，比2023年第二季度的303,935美元增長了3%。這一增長得益於互補健康療法營業收入增長33.1%，達到了230,536美元，彌補了由於產品範圍有限導致的網絡營銷業務營業收入下降67.7%。毛利潤率從去年的64.5%降至61.8%，而營業費用則增加了16.5%，達到了647,146美元，主要是由於董事薪酬和納斯達克上市費用導致的一般和管理費用增加。公司記錄了31,110美元的其他收入，而去年同期的費用爲22,355美元。淨虧損從2023年第二季度的379,449美元擴大至432,315美元。截至2024年6月30日，公司仍保持強大的流動性，現金及現金等價物爲316萬，但較2023年年底的483萬有所下降。管理層繼續專注於擴展其互補健康療法業務，同時努力解決網絡營銷部門面臨的挑戰。
Agape ATP公司報告了2024年第二季度營業收入爲313,039美元，比2023年第二季度的303,935美元增長了3%。這一增長得益於互補健康療法營業收入增長33.1%，達到了230,536美元，彌補了由於產品範圍有限導致的網絡營銷業務營業收入下降67.7%。毛利潤率從去年的64.5%降至61.8%，而營業費用則增加了16.5%，達到了647,146美元，主要是由於董事薪酬和納斯達克上市費用導致的一般和管理費用增加。公司記錄了31,110美元的其他收入，而去年同期的費用爲22,355美元。淨虧損從2023年第二季度的379,449美元擴大至432,315美元。截至2024年6月30日，公司仍保持強大的流動性，現金及現金等價物爲316萬，但較2023年年底的483萬有所下降。管理層繼續專注於擴展其互補健康療法業務，同時努力解決網絡營銷部門面臨的挑戰。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    WK Kellogg
    KLG
    -- 19.760
    日日煮
    DDC
    -- 0.175
    榮業食品
    WYHG
    -- 8.600
    康寶萊
    HLF
    -- 5.620
    Above Food Ingredients
    ABVE
    -- 0.569
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    美聯儲暫停降息，你如何調整持倉？
    美聯儲宣布基準利率維持在4.25%—4.50%不變，符合市場預期。你會如何配置資產？ 展开
    FOMC新聞發佈會，2025年1月29日